Clinical trials: Urinary System Tumor
Transitional Cell Carcinoma
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Biological therapies, such as Bacille Calmette Guerin (BCG) and sargramostim (GM-CSF), use different ways to stimulate the…
- Trial name
- NCT00070070
- Testing
- TICE®-strain BCG, NY-ESO-1 protein, sargramostim
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ludwig Institute for Cancer Research
Renal Cell Carcinoma
Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma
Adverse events (AEs) with Cabozantinib are frequent (about 40-67% of patients) and often lead to temporary treatment interruptions, dose reductions or permanent discontinuations, potentially reducing dose intensity and sustained…
- Trial name
- IMPACT (NCT07805122)
- Testing
- Intensified Monitoring of Pharmacology
- Where
- Italy
- Volunteers
- 216 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
This phase I/II trial is studying the side effects and best dose of sorafenib, gemcitabine, and capecitabine and to see how well they work in treating patients with unresectable and/or metastatic kidney cancer.
- Conditions
- Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT00121251
- Testing
- Capecitabine, Gemcitabine Hydrochloride, Sorafenib Tosylate
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Genetic Susceptibility to Kidney Cancer
This study will further the understanding of the genetic events leading to the development of RCC.
- Trial name
- NCT00854022
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Baylor College of Medicine
Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
This phase II trial tests how well the combination of futibatinib and durvalumab given before cystectomy works in treating patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based therapy.
- Conditions
- Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT06263153
- Testing
- Biospecimen Collection, Computed Tomography, Durvalumab
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Yuanquan Yang
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Renal Cell Carcinoma
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
To investigate the safety of Nivolumab in combination with Ipilimumab in subjects with previously untreated advanced or metastatic Renal Cell Cancer.
- Trial name
- CHECKMATE 920 (NCT02982954)
- Testing
- Nivolumab, Ipilimumab
- Where
- 61 sites in United States
- Volunteers
- 211 people
- Sponsor
- Bristol-Myers Squibb
Kidney Cancer, Melanoma (Skin)
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00550654
- Testing
- questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
- Trial name
- NCT05783622
- Testing
- JANX008
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janux Therapeutics
Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0)…
- Conditions
- Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
- Trial name
- NCT07389629
- Testing
- QL1706 Combined With Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread from where…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT02496208
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate
- Where
- 8 sites in United States
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer
Low grade non-muscle-invasive bladder cancer (NMIBC) often recurs after treatment, requiring repeated surgeries, especially in older patients.
- Trial name
- DutaBCa-1 (NCT07420517)
- Testing
- Dutasteride (0.5mg)
- Where
- Canada
- Volunteers
- 95 people
- Sponsor
- Paul Toren
Carcinoma, Renal Cell
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
The main purpose of this study is to expand knowledge on the effectiveness of Avelumab intravenous infusion in combination with Axitinib as the first-line therapy in participants with advanced renal-cell carcinoma (aRCC) in…
- Trial name
- NCT04941768
- Where
- 61 sites in Belgium, Germany and 2 more
- Volunteers
- 105 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Bladder Cancer
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
Patients older than ≥18 years, with muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient's refusal. This study is designed as a multicentre, single-arm phase II study.
- Trial name
- BladderSpar (NCT03697850)
- Testing
- Atezolizumab
- Where
- 12 sites in France
- Volunteers
- 79 people
- Sponsor
- UNICANCER
Bladder Cancer
Performance, Feasibility, and Safety Study for a Novel Endoluminal Robotic System for En-Bloc Resection of Bladder Tumours: First-In-Human Trial
This is a prospective, single-arm study to evaluate the feasibility and safety of performing transurethral en-bloc resection of bladder tumours using the Zenith robotic system.
- Trial name
- NCT06281080
- Testing
- En-Bloc Resection of Bladder Tumours
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Chinese University of Hong Kong
Rhabdomyosarcoma, Ewing Sarcoma
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
This is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy…
- Conditions
- Rhabdomyosarcoma, Ewing Sarcoma, Neuroblastoma, Wilms Tumor
- Trial name
- SABRE (NCT07172958)
- Testing
- Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Children's National Research Institute
Advanced Solid Tumors, NSCLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have…
- Conditions
- Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC
- Trial name
- NCT04157985
- Testing
- Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Dan Zandberg
Surgery, Renal Cancer
Effects of Anesthesia on Immunity in Cancer
The aim of the study is a comparative study of the cellular immunity response of patients operated on for kidney cancer under total intravenous and inhalational anesthesia.
- Trial name
- NCT03514550
- Testing
- Propofol, Sevoflurane, Epidural block
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Bladder Cancer, Cervical Cancer
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00666978
- Testing
- smoking cessation intervention, bupropion hydrochloride, gene expression analysis
- Where
- 2 sites in United States
- Volunteers
- 540 people
- Sponsor
- Lisa Sanderson Cox, PhD
Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
This is a prospective, multicenter, randomized controlled superiority study designed to evaluate whether the addition of pelvic lymph node dissection improves bladder-intact event-free survival in patients with cT2-3N0M0 bladder…
- Conditions
- Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer, Bladder Cancer
- Trial name
- NCT07756008
- Testing
- Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Tianjin Medical University Second Hospital